Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can Indian CRAMS firms cash in on the global slowdown?

This article was originally published in Scrip

Executive Summary

Will the global economic slowdown brighten short-term outsourcing prospects or would it cast a pall over India's custom research and manufacturing services (CRAMS) segment that is projected to touch $7.6 billion by 2012? While the jury is still out on the segment's prospects amid the turmoil, experts say that Indian CRAMS firms may have to offer more than mere cost arbitrage to rake in the moolah.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC014585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel